GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Total Current Assets

Sino Biopharmaceutical (HKSE:01177) Total Current Assets : HK$26,038 Mil (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Sino Biopharmaceutical Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Sino Biopharmaceutical's total current assets for the quarter that ended in Dec. 2023 was HK$26,038 Mil.

Sino Biopharmaceutical Total Current Assets Historical Data

The historical data trend for Sino Biopharmaceutical's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sino Biopharmaceutical Total Current Assets Chart

Sino Biopharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Current Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27,722.07 27,020.99 28,778.87 28,961.89 26,037.99

Sino Biopharmaceutical Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Total Current Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 28,778.87 29,536.77 28,961.89 29,507.21 26,037.99

Sino Biopharmaceutical Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Sino Biopharmaceutical's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=15442.162+6779.91+2180.418+1635.497
=26,038

Sino Biopharmaceutical's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets=Cash, Cash Equivalents, Marketable Securities+Total Receivables+Total Inventories+Other Current Assets
=15442.162+6779.91+2180.418+1635.497
=26,038

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Sino Biopharmaceutical  (HKSE:01177) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Sino Biopharmaceutical's Liquidation Value for the quarter that ended in Dec. 2023 is

Liquidation value
= Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=15442.162-27820.119+0.75 * 4131.659+0.5 * 2180.418
=-8,189

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sino Biopharmaceutical Total Current Assets Related Terms

Thank you for viewing the detailed overview of Sino Biopharmaceutical's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Sino Biopharmaceutical (HKSE:01177) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sino Biopharmaceutical Ltd (HKSE:01177) » Definitions » Total Current Assets
Comparable Companies
HKSE:02269 HKSE:01801 HKSE:06990 HKSE:09926 HKSE:01877 HKSE:09995 HKSE:01548 HKSE:01530 HKSE:06826 HKSE:02696 OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB BNTX XBRU:ARGX
Traded in Other Exchanges
SBHMY:USA SBMFF:USA SMZ1:Germany
Address
1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Website
https://www.sinobiopharm.com
Sino Biopharmaceutical Co, or SBP, is one of the largest drugmakers in China, with CNY 27 billion revenue in 2021. Its four most important therapeutic areas are oncology, hepatitis, cardio-cerebral, and respiratory medicines. SBP's current portfolio is mostly generics, and some key drugs are facing severe price reductions. However, it also has a rich pipeline of early-to-market generics and biosimilars, especially in oncology and respiratory treatments.
Executives
Tse Eric S Y 2101 Beneficial owner
Tse Ping 2101 Beneficial owner
Cheng Cheung Ling 2101 Beneficial owner
True Merit Global Limited 2101 Beneficial owner
Tse Theresa Y Y 2101 Beneficial owner
Thousand Eagles Limited 2101 Beneficial owner
France Investment (china 1) Group Limited 2101 Beneficial owner
Remarkable Industries Limited 2101 Beneficial owner
Validated Profits Limited 2101 Beneficial owner

Sino Biopharmaceutical (HKSE:01177) Headlines

No Headlines